Advertisement
IFRX Новости Форекс
InflaRx Reports Positive Topline Results From SAD Phase I Study With C5aR Inhibitor INF904
Biotechnology company InflaRx N.V. (IFRX) announced Monday topline results from the single ascending dose (SAD) part of its randomized, double-blind, placebo-controlled Phase I trial of the orally administered, low molecular weight C5aR inhibitor INF904.
RTTNews
|
642 дней спустя
